270 related articles for article (PubMed ID: 19332246)
21. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
[TBL] [Abstract][Full Text] [Related]
22. [Related-factor analysis on efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma].
Cheng XD; Lü WG; Xie X; Huang XF; Ye DF; He HC; Ding ZM
Zhonghua Fu Chan Ke Za Zhi; 2003 Nov; 38(11):670-2. PubMed ID: 14728853
[TBL] [Abstract][Full Text] [Related]
23. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.
Markman M
Trends Pharmacol Sci; 2008 Oct; 29(10):515-9. PubMed ID: 18760845
[TBL] [Abstract][Full Text] [Related]
24. Prolonged disease-free and treatment-free survival in platinum-resistant ovarian cancer following extended (>1 year) administration of single-agent paclitaxel: A case report and discussion of potential clinical implications.
Markman M; Webster K; Kulp B; Peterson G
Cancer Invest; 2005; 23(1):33-5. PubMed ID: 15779866
[TBL] [Abstract][Full Text] [Related]
25. Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples.
Ng TY; Ngan HY; Cheng DK; Wong LC
Gynecol Oncol; 2000 Mar; 76(3):405-8. PubMed ID: 10684718
[TBL] [Abstract][Full Text] [Related]
26. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.
Muggia FM
Semin Oncol; 2004 Dec; 31(6 Suppl 14):17-24. PubMed ID: 15726530
[TBL] [Abstract][Full Text] [Related]
27. Surgical management of recurrent ovarian cancer.
Leitao MM; Chi DS
Semin Oncol; 2009 Apr; 36(2):106-11. PubMed ID: 19332245
[TBL] [Abstract][Full Text] [Related]
28. Management of recurrent epithelial ovarian carcinoma.
Vasey PA
Aust N Z J Obstet Gynaecol; 2005 Aug; 45(4):269-77. PubMed ID: 16029291
[TBL] [Abstract][Full Text] [Related]
29. Emerging therapeutic options for platinum-sensitive ovarian cancer patients.
Armstrong DK; Coleman RL; Penson RT
Clin Adv Hematol Oncol; 2011 Apr; 9(4 Suppl 5):1-16. PubMed ID: 21558997
[TBL] [Abstract][Full Text] [Related]
30. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.
Fagotti A; Paris I; Grimolizzi F; Fanfani F; Vizzielli G; Naldini A; Scambia G
Gynecol Oncol; 2009 Jun; 113(3):335-40. PubMed ID: 19345401
[TBL] [Abstract][Full Text] [Related]
31. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
32. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Aghajanian C; Blessing JA; Darcy KM; Reid G; DeGeest K; Rubin SC; Mannel RS; Rotmensch J; Schilder RJ; Riordan W;
Gynecol Oncol; 2009 Nov; 115(2):215-20. PubMed ID: 19712963
[TBL] [Abstract][Full Text] [Related]
33. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.
Tewari KS; Monk BJ
Semin Oncol; 2009 Apr; 36(2):170-80. PubMed ID: 19332251
[TBL] [Abstract][Full Text] [Related]
34. [Second-line treatment using novel chemotherapeutic and biologic agents].
Sugiyama T
Gan To Kagaku Ryoho; 2009 May; 36(5):730-5. PubMed ID: 19461172
[TBL] [Abstract][Full Text] [Related]
35. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
[TBL] [Abstract][Full Text] [Related]
36. Second-line chemotherapy of epithelial ovarian cancer.
Markmon M
Expert Rev Anticancer Ther; 2003 Feb; 3(1):31-6. PubMed ID: 12597347
[TBL] [Abstract][Full Text] [Related]
37. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
Monk BJ; Coleman RL
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S63-7. PubMed ID: 19955917
[TBL] [Abstract][Full Text] [Related]
38. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
Saldivar JS; Wu X; Follen M; Gershenson D
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
[TBL] [Abstract][Full Text] [Related]
39. Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study.
Fotopoulou C; Cho CH; Kraetschell R; Gellermann J; Wust P; Lichtenegger W; Sehouli J
Int J Hyperthermia; 2010; 26(2):118-26. PubMed ID: 20146566
[TBL] [Abstract][Full Text] [Related]
40. "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?
Davis A; Tinker AV; Friedlander M
Gynecol Oncol; 2014 Jun; 133(3):624-31. PubMed ID: 24607285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
